SMOC1 and neoplasm: Among them, GINS3 was characterized by high tumor purity, immune-desert, activation of EGFR and ephrin receptors, chromosomal instability, fewer KRAS mutations, SMOC1 methylation, immunotherapeutic resistance, and high sensitivity to cetuximab and bevacizumab.